Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- S&P 500, Nasdaq futures slip as investors eye SK Hynix listing, Middle East risks
- Oil heads for weekly gain as Middle East supply risks persist
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results
February 14, 2018 4:01 PM ESTWASHINGTON, Feb. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2017.
Key Highlights:
Total net product sales from HETLIOZ® and Fanapt® were $44.3 million in the fourth quarter of 2017, a 7% increase compared to $41.3 million in the third quarter of 2017 and a 16% increase compared to $38.2 million in the fourth quarter of 2016.HETLIOZ® (tasimelteon)
HETLIOZ® net product sales were $25.0 million in the fourth quarter of 2017, a 12% increase compared to $22.3 million in... More